This CagA-PI3K/AKT-Sp1-RBP2-Cyclin D1 pathway may be a novel mechanism for the switch from inflammation to GC development and the key bridge molecule RBP2 may have potential therapeutic advantages. This evidence concerns the gene S100A8 and gastric cancer.